Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.
Panelist discusses how the misalignment between Hurley stages and patient burden in hidradenitis suppurativa (HS) creates diagnostic and treatment challenges. Current Hurley staging inadequately captures the full patient experience, potentially leading to suboptimal treatment approaches. Standardized clinical training and assessment tools that incorporate both objective staging and subjective patient-reported outcomes could help bridge this gap, enabling more personalized and comprehensive HS management.
Dr. Bijal Shah explores the recent advancements and shifts in treatment strategies for Ph+ ALL, driven by innovations in targeted therapies and evolving clinical practices
A panelist discusses how enhanced screening protocols combined with predictive analytics can accelerate Lambert-Eaton myasthenic syndrome (LEMS) detection in high-risk populations like patients with small cell lung cancer (SCLC) while also exploring the potential of telemedicine to improve early diagnosis in underserved communities.
A panelist discusses how uncomplicated urinary tract infections (UTIs) typically affect otherwise healthy individuals and can be treated with short-course antibiotics by primary care physicians, while complicated UTIs involve underlying conditions or anatomical abnormalities requiring specialized care from urologists, infectious disease specialists, and other healthcare providers working collaboratively to optimize treatment outcomes through coordinated multidisciplinary management.
Panelists discuss how a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma affects patients physically and emotionally and how these challenges shape their treatment journey and overall care.
Dr. Bijal Shah highlights the critical role of evidence-based guidelines, including NCCN recommendations, in standardizing care and enhancing outcomes for patients with Ph+ ALL.
Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of monocytes into macrophages, contributing to inflammation and fibrosis in the disease.
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
Panelist discusses how hidradenitis suppurativa’s early detection is challenging due to misdiagnosis, patient stigma, and limited awareness. Improved physician education, proactive screening, and strategic use of claims data can help identify undiagnosed cases earlier, enabling more timely intervention and management.
Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.
Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.
Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.
Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.
Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact treatment strategies by improving progression-free survival, while also addressing potential drawbacks of intervening too early in the disease course.
Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, and reduced erythropoietin synthesis, resulting in both functional and absolute iron deficiency alongside diminished red blood cell production.
A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.
A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.
Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.
The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.
